Lipid peroxides in obese patients and effects of weight loss with orlistat on lipid peroxides levels
Obesity is a well-known risk factor of atherosclerosis. Recent studies showed that obesity is associated with enhanced lipid peroxidation. The aim of this study is to investigate the effect of weight reduction with orlistat treatment on lipid peroxidation levels. We assessed lipid peroxidation by me...
Gespeichert in:
| Veröffentlicht in: | International Journal of Obesity 2005-01, Vol.29 (1), p.142-145 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 145 |
|---|---|
| container_issue | 1 |
| container_start_page | 142 |
| container_title | International Journal of Obesity |
| container_volume | 29 |
| creator | YESILBURSA, D SERDAR, Z SERDAR, A SARAC, M COSKUN, S JALE, C |
| description | Obesity is a well-known risk factor of atherosclerosis. Recent studies showed that obesity is associated with enhanced lipid peroxidation. The aim of this study is to investigate the effect of weight reduction with orlistat treatment on lipid peroxidation levels. We assessed lipid peroxidation by measuring the concentration of plasma malondialdehyde (MDA).
A randomized, controlled, open-label 6-month study.
In total, 36 obese (body mass index (BMI) >30 kg/m2) and 11 healthy age-matched control subjects were enrolled in the study.
Fasting glucose, triglyceride, total cholesterol, HDL cholesterol and LDL cholesterol and MDA levels were measured in both groups. Obese subjects received orlistat, 120 mg three times daily together with hypocaloric diet. After 6 months of treatment laboratory tests were repeated.
MDA levels were significantly higher in obese patients than the control group (P |
| doi_str_mv | 10.1038/sj.ijo.0802794 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_67323745</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A188448519</galeid><sourcerecordid>A188448519</sourcerecordid><originalsourceid>FETCH-LOGICAL-c482t-461c9e161c45f04f4f658aaf0731eb5dc7cc76f92b173fe9dec1919a623088d93</originalsourceid><addsrcrecordid>eNpd0c1vFCEUAHBiNHZbvXrTEBO9zQoMDDPHptFqsokXPROWeXSZsDAC0-p_L7qj1YYECPm9j_AQekHJlpK2f5enrZvilvSEyYE_QhvKZdcIPsjHaENaIhsiOnGGznOeCCFCEPYUnVHBOyml2KBx52Y34hlS_O5GyNgFHPeQAc-6OAglYx1GDNaCqfdo8R24m0PBPuaM71w54Ji8y0UXHAP2D7J5uAWfn6EnVvsMz9fzAn398P7L1cdm9_n609XlrjG8Z6XhHTUD0LpzYQm33Hai19oS2VLYi9FIY2RnB7ansrUwjGDoQAfdsZb0_Ti0F-jtKe-c4rcFclFHlw14rwPEJatOtqyVXFT4-gGc4pJC7U0xOjBJWMcr2p7QjfagXLCxJG3qGuHoTAxgXX2_pH3PeS_oP-V_BxxA-3LI0S_FxZD_h2tmk-ovJrBqTu6o0w9Fifo1VpUnVceq1rHWgFdrv8v-COM9X-dYwZsV6Gy0t0kH4_K967gUhLLqXp5c0GVJ8Bf8KfQTHYS0pg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219270264</pqid></control><display><type>article</type><title>Lipid peroxides in obese patients and effects of weight loss with orlistat on lipid peroxides levels</title><source>MEDLINE</source><source>Nature</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>YESILBURSA, D ; SERDAR, Z ; SERDAR, A ; SARAC, M ; COSKUN, S ; JALE, C</creator><creatorcontrib>YESILBURSA, D ; SERDAR, Z ; SERDAR, A ; SARAC, M ; COSKUN, S ; JALE, C</creatorcontrib><description>Obesity is a well-known risk factor of atherosclerosis. Recent studies showed that obesity is associated with enhanced lipid peroxidation. The aim of this study is to investigate the effect of weight reduction with orlistat treatment on lipid peroxidation levels. We assessed lipid peroxidation by measuring the concentration of plasma malondialdehyde (MDA).
A randomized, controlled, open-label 6-month study.
In total, 36 obese (body mass index (BMI) >30 kg/m2) and 11 healthy age-matched control subjects were enrolled in the study.
Fasting glucose, triglyceride, total cholesterol, HDL cholesterol and LDL cholesterol and MDA levels were measured in both groups. Obese subjects received orlistat, 120 mg three times daily together with hypocaloric diet. After 6 months of treatment laboratory tests were repeated.
MDA levels were significantly higher in obese patients than the control group (P<0.0001). After 6 months of treatment in obese subjects, the mean weight of the patients decreased by 6.8 kg, the BMI by 3.2 kg/m2. Plasma MDA levels were significantly reduced by weight loss from 2+/-0.77 to 0.89+/-0.41 nmol/ml (P<0.001). BMI correlated with MDA levels at baseline (r=0.6, P<0.0001). Changes in BMI was positively associated with plasma MDA level reduction (r=0.36, P<0.05).
These results indicate that obesity is associated with increases in endogenous lipid peroxides. Our data show that the indicator of lipid peroxidation-MDA-falls markedly in association with weight loss with orlistat. The demonstration of decreased free radical generation has important implications for oxidative mechanism underlying obesity-associated disorders.</description><identifier>ISSN: 0307-0565</identifier><identifier>EISSN: 1476-5497</identifier><identifier>DOI: 10.1038/sj.ijo.0802794</identifier><identifier>PMID: 15467775</identifier><identifier>CODEN: IJOBDP</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing</publisher><subject>Adult ; Biological and medical sciences ; Biomarkers - blood ; Body Mass Index ; Case-Control Studies ; Cholesterol ; Diet, Reducing ; Female ; General and cellular metabolism. Vitamins ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use ; Laboratory tests ; Lactones - therapeutic use ; Lipid Peroxidation ; Male ; Malondialdehyde - blood ; Medical sciences ; Metabolic diseases ; Middle Aged ; Obesity ; Obesity - diet therapy ; Obesity - drug therapy ; Obesity - metabolism ; Peroxidation ; Pharmacology. Drug treatments ; Risk factors</subject><ispartof>International Journal of Obesity, 2005-01, Vol.29 (1), p.142-145</ispartof><rights>2005 INIST-CNRS</rights><rights>COPYRIGHT 2005 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jan 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c482t-461c9e161c45f04f4f658aaf0731eb5dc7cc76f92b173fe9dec1919a623088d93</citedby><cites>FETCH-LOGICAL-c482t-461c9e161c45f04f4f658aaf0731eb5dc7cc76f92b173fe9dec1919a623088d93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,2728,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16475012$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15467775$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>YESILBURSA, D</creatorcontrib><creatorcontrib>SERDAR, Z</creatorcontrib><creatorcontrib>SERDAR, A</creatorcontrib><creatorcontrib>SARAC, M</creatorcontrib><creatorcontrib>COSKUN, S</creatorcontrib><creatorcontrib>JALE, C</creatorcontrib><title>Lipid peroxides in obese patients and effects of weight loss with orlistat on lipid peroxides levels</title><title>International Journal of Obesity</title><addtitle>Int J Obes (Lond)</addtitle><description>Obesity is a well-known risk factor of atherosclerosis. Recent studies showed that obesity is associated with enhanced lipid peroxidation. The aim of this study is to investigate the effect of weight reduction with orlistat treatment on lipid peroxidation levels. We assessed lipid peroxidation by measuring the concentration of plasma malondialdehyde (MDA).
A randomized, controlled, open-label 6-month study.
In total, 36 obese (body mass index (BMI) >30 kg/m2) and 11 healthy age-matched control subjects were enrolled in the study.
Fasting glucose, triglyceride, total cholesterol, HDL cholesterol and LDL cholesterol and MDA levels were measured in both groups. Obese subjects received orlistat, 120 mg three times daily together with hypocaloric diet. After 6 months of treatment laboratory tests were repeated.
MDA levels were significantly higher in obese patients than the control group (P<0.0001). After 6 months of treatment in obese subjects, the mean weight of the patients decreased by 6.8 kg, the BMI by 3.2 kg/m2. Plasma MDA levels were significantly reduced by weight loss from 2+/-0.77 to 0.89+/-0.41 nmol/ml (P<0.001). BMI correlated with MDA levels at baseline (r=0.6, P<0.0001). Changes in BMI was positively associated with plasma MDA level reduction (r=0.36, P<0.05).
These results indicate that obesity is associated with increases in endogenous lipid peroxides. Our data show that the indicator of lipid peroxidation-MDA-falls markedly in association with weight loss with orlistat. The demonstration of decreased free radical generation has important implications for oxidative mechanism underlying obesity-associated disorders.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Body Mass Index</subject><subject>Case-Control Studies</subject><subject>Cholesterol</subject><subject>Diet, Reducing</subject><subject>Female</subject><subject>General and cellular metabolism. Vitamins</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</subject><subject>Laboratory tests</subject><subject>Lactones - therapeutic use</subject><subject>Lipid Peroxidation</subject><subject>Male</subject><subject>Malondialdehyde - blood</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Middle Aged</subject><subject>Obesity</subject><subject>Obesity - diet therapy</subject><subject>Obesity - drug therapy</subject><subject>Obesity - metabolism</subject><subject>Peroxidation</subject><subject>Pharmacology. Drug treatments</subject><subject>Risk factors</subject><issn>0307-0565</issn><issn>1476-5497</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpd0c1vFCEUAHBiNHZbvXrTEBO9zQoMDDPHptFqsokXPROWeXSZsDAC0-p_L7qj1YYECPm9j_AQekHJlpK2f5enrZvilvSEyYE_QhvKZdcIPsjHaENaIhsiOnGGznOeCCFCEPYUnVHBOyml2KBx52Y34hlS_O5GyNgFHPeQAc-6OAglYx1GDNaCqfdo8R24m0PBPuaM71w54Ji8y0UXHAP2D7J5uAWfn6EnVvsMz9fzAn398P7L1cdm9_n609XlrjG8Z6XhHTUD0LpzYQm33Hai19oS2VLYi9FIY2RnB7ansrUwjGDoQAfdsZb0_Ti0F-jtKe-c4rcFclFHlw14rwPEJatOtqyVXFT4-gGc4pJC7U0xOjBJWMcr2p7QjfagXLCxJG3qGuHoTAxgXX2_pH3PeS_oP-V_BxxA-3LI0S_FxZD_h2tmk-ovJrBqTu6o0w9Fifo1VpUnVceq1rHWgFdrv8v-COM9X-dYwZsV6Gy0t0kH4_K967gUhLLqXp5c0GVJ8Bf8KfQTHYS0pg</recordid><startdate>20050101</startdate><enddate>20050101</enddate><creator>YESILBURSA, D</creator><creator>SERDAR, Z</creator><creator>SERDAR, A</creator><creator>SARAC, M</creator><creator>COSKUN, S</creator><creator>JALE, C</creator><general>Nature Publishing</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T2</scope><scope>7TK</scope><scope>7TS</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20050101</creationdate><title>Lipid peroxides in obese patients and effects of weight loss with orlistat on lipid peroxides levels</title><author>YESILBURSA, D ; SERDAR, Z ; SERDAR, A ; SARAC, M ; COSKUN, S ; JALE, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c482t-461c9e161c45f04f4f658aaf0731eb5dc7cc76f92b173fe9dec1919a623088d93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Body Mass Index</topic><topic>Case-Control Studies</topic><topic>Cholesterol</topic><topic>Diet, Reducing</topic><topic>Female</topic><topic>General and cellular metabolism. Vitamins</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use</topic><topic>Laboratory tests</topic><topic>Lactones - therapeutic use</topic><topic>Lipid Peroxidation</topic><topic>Male</topic><topic>Malondialdehyde - blood</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Middle Aged</topic><topic>Obesity</topic><topic>Obesity - diet therapy</topic><topic>Obesity - drug therapy</topic><topic>Obesity - metabolism</topic><topic>Peroxidation</topic><topic>Pharmacology. Drug treatments</topic><topic>Risk factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YESILBURSA, D</creatorcontrib><creatorcontrib>SERDAR, Z</creatorcontrib><creatorcontrib>SERDAR, A</creatorcontrib><creatorcontrib>SARAC, M</creatorcontrib><creatorcontrib>COSKUN, S</creatorcontrib><creatorcontrib>JALE, C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>International Journal of Obesity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YESILBURSA, D</au><au>SERDAR, Z</au><au>SERDAR, A</au><au>SARAC, M</au><au>COSKUN, S</au><au>JALE, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipid peroxides in obese patients and effects of weight loss with orlistat on lipid peroxides levels</atitle><jtitle>International Journal of Obesity</jtitle><addtitle>Int J Obes (Lond)</addtitle><date>2005-01-01</date><risdate>2005</risdate><volume>29</volume><issue>1</issue><spage>142</spage><epage>145</epage><pages>142-145</pages><issn>0307-0565</issn><eissn>1476-5497</eissn><coden>IJOBDP</coden><abstract>Obesity is a well-known risk factor of atherosclerosis. Recent studies showed that obesity is associated with enhanced lipid peroxidation. The aim of this study is to investigate the effect of weight reduction with orlistat treatment on lipid peroxidation levels. We assessed lipid peroxidation by measuring the concentration of plasma malondialdehyde (MDA).
A randomized, controlled, open-label 6-month study.
In total, 36 obese (body mass index (BMI) >30 kg/m2) and 11 healthy age-matched control subjects were enrolled in the study.
Fasting glucose, triglyceride, total cholesterol, HDL cholesterol and LDL cholesterol and MDA levels were measured in both groups. Obese subjects received orlistat, 120 mg three times daily together with hypocaloric diet. After 6 months of treatment laboratory tests were repeated.
MDA levels were significantly higher in obese patients than the control group (P<0.0001). After 6 months of treatment in obese subjects, the mean weight of the patients decreased by 6.8 kg, the BMI by 3.2 kg/m2. Plasma MDA levels were significantly reduced by weight loss from 2+/-0.77 to 0.89+/-0.41 nmol/ml (P<0.001). BMI correlated with MDA levels at baseline (r=0.6, P<0.0001). Changes in BMI was positively associated with plasma MDA level reduction (r=0.36, P<0.05).
These results indicate that obesity is associated with increases in endogenous lipid peroxides. Our data show that the indicator of lipid peroxidation-MDA-falls markedly in association with weight loss with orlistat. The demonstration of decreased free radical generation has important implications for oxidative mechanism underlying obesity-associated disorders.</abstract><cop>Basingstoke</cop><pub>Nature Publishing</pub><pmid>15467775</pmid><doi>10.1038/sj.ijo.0802794</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0307-0565 |
| ispartof | International Journal of Obesity, 2005-01, Vol.29 (1), p.142-145 |
| issn | 0307-0565 1476-5497 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67323745 |
| source | MEDLINE; Nature; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Adult Biological and medical sciences Biomarkers - blood Body Mass Index Case-Control Studies Cholesterol Diet, Reducing Female General and cellular metabolism. Vitamins Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Laboratory tests Lactones - therapeutic use Lipid Peroxidation Male Malondialdehyde - blood Medical sciences Metabolic diseases Middle Aged Obesity Obesity - diet therapy Obesity - drug therapy Obesity - metabolism Peroxidation Pharmacology. Drug treatments Risk factors |
| title | Lipid peroxides in obese patients and effects of weight loss with orlistat on lipid peroxides levels |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T09%3A44%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipid%20peroxides%20in%20obese%20patients%20and%20effects%20of%20weight%20loss%20with%20orlistat%20on%20lipid%20peroxides%20levels&rft.jtitle=International%20Journal%20of%20Obesity&rft.au=YESILBURSA,%20D&rft.date=2005-01-01&rft.volume=29&rft.issue=1&rft.spage=142&rft.epage=145&rft.pages=142-145&rft.issn=0307-0565&rft.eissn=1476-5497&rft.coden=IJOBDP&rft_id=info:doi/10.1038/sj.ijo.0802794&rft_dat=%3Cgale_proqu%3EA188448519%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219270264&rft_id=info:pmid/15467775&rft_galeid=A188448519&rfr_iscdi=true |